NYXH logo

NYXOAH SA

NYXHNASDAQ
🏆 #3940 by market capEarnings Nov 5US Equity
$1.39▼ $0.20 (−14.51%)
After hours · at close
🔔
Track NYXH
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 14.5%
7d▼ 0.4%
14d▼ 9.5%
30d▼ 13.2%
ytd▼ 69.9%
1y▼ 68.7%
🏦Market Cap
$139M
Small Cap
📈Revenue Growth (YoY)
+121.6%
High Growth
📊Gross Margin
51.3%
Healthy
💵FCF Margin
-326.1%
Thin
⚖️P/S Ratio
5.3x
Fair
Otter Score
76
Good

Trading Snapshot

Day Range
$1.38 – $1.41
52-Week Range
$1.26 – $6.88
Volume
$3.26B
Avg Volume
$3.31B
Shares Outstanding
100.1M
Next Earnings
Nov 4, 2026

Fundamentals Snapshot

Annual Revenue
$10M
Last Q Revenue
$8M
P/E Ratio
-0.6
P/S Ratio
5.3x
EPS (TTM)
$-1.73
Dividend Yield
0.00%
Dilution (1yr)
+8.3%

Why Investors Own NYXH

  • ✓High-growth profile — revenue up +6.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 49% gross margin and 22% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NYXH logo

NYXOAH SA

NYXH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$10M▲ +121.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
63.1%▼ −3.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$83M▲ +41.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$68M▲ +23.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
40.1M▲ +8.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$10M▼ −$22M YoY
StockOtter · stockotter.space

About NYXOAH SA

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$1.43
▲ +3.0% Upside
High Target$1.76
Low Target$1.12
Based on 21 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

NYXOAH SA tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift NYXH price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

NYXOAH SA announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.